

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. Securities may not be offered or sold in the United States in the absence of registration or an exemption from registration. Neither this announcement nor any content contained herein shall form the basis of any contract or commitment whatsoever. Such offer or invitation will be made only by means of a prospectus and only in jurisdictions in which such offer or invitation may legally and validly be made.



CK Life Sciences Int'l., (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

ANNOUNCEMENT

SPIN-OFF PROPOSAL

The board of directors (“**Board**”) of CK Life Sciences Int'l., (Holdings) Inc. (the “**Company**”) announces that on 13 June 2012, the Company submitted a spin-off proposal to The Hong Kong Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) pursuant to Practice Note 15 to the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”) in relation to the proposed spin-off of its business of research and development of immunotherapy solutions for cancer, currently carried on by its indirect non wholly-owned subsidiary, Polynoma LLC (“**Polynoma**”). Specifically, the Company is considering a series of transactions involving the reorganisation of the Company’s interests in Polynoma such that Polynoma, Inc. (“**New Co**”) will become the holding company of Polynoma, in anticipation of a proposed initial public offering of New Co shares on the NASDAQ Stock Market in the United States of America (“**Spin-off Proposal**”).

It is intended that upon completion of the Spin-off Proposal, the Company will own approximately 49.3% to 58.5% of the issued share capital in New Co. The Board expects that the Spin-off Proposal will constitute a discloseable transaction for the Company. Pursuant to Practice Note 15 to the Listing Rules, the Company is required to provide its shareholders (“**Shareholders**”) with an assured entitlement to the share capital in New Co. The Company has obtained confirmation from the Stock Exchange that it may proceed with the Spin-off Proposal and if the Spin-off Proposal is to be proceeded with, the Board intends to provide the assured entitlement by way of a distribution in specie of certain amount of the Company’s interest in New Co as the Board may subsequently determine (“**Distribution in specie**”).

The terms of the Spin-off Proposal, including offer size, price range and the assured entitlement for Shareholders required under Practice Note 15 to the Listing Rules, have not yet been finalised. Further announcement(s) will be made by the Company in this regard as and when appropriate.

In connection with the Spin-off Proposal, New Co proposes to adopt an equity incentive plan (“**Polynoma Equity Incentive Plan**”), pursuant to which options to subscribe for shares of common stock in New Co would be granted to certain grantees (“**Proposed Grant**”). The Company proposes to hold an extraordinary general meeting for the Shareholders to consider and, if thought fit, approve (i) the adoption of the Polynoma Equity Incentive Plan, (ii) the Proposed Grant and (iii) the Distribution in specie. The Company will despatch a circular to the Shareholders to provide further information on the above as and when appropriate.

Shareholders and potential investors should note that the Spin-off Proposal is subject to, among other things, the final decision of the Board and approval from the Stock Exchange, the U.S. Securities and Exchange Commission and the U.S. national securities exchange upon which the shares of New Co are to be listed, if any, and there is no assurance that the Spin-off Proposal will take place or as to when it may take place. Accordingly, Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int’l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 10 August 2012

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).